Jaguar Health Past Earnings Performance
Past criteria checks 0/6
Jaguar Health's earnings have been declining at an average annual rate of -1.7%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 14.3% per year.
Key information
-1.7%
Earnings growth rate
96.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 14.3% |
| Return on equity | -271.8% |
| Net Margin | -377.9% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Jaguar Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 10 | -38 | 22 | 18 |
| 31 Dec 23 | 10 | -41 | 23 | 19 |
| 30 Sep 23 | 11 | -40 | 22 | 19 |
| 30 Jun 23 | 11 | -44 | 24 | 19 |
| 31 Mar 23 | 11 | -42 | 24 | 17 |
| 31 Dec 22 | 12 | -47 | 27 | 18 |
| 30 Sep 22 | 11 | -54 | 29 | 19 |
| 30 Jun 22 | 8 | -54 | 29 | 16 |
| 31 Mar 22 | 6 | -59 | 29 | 18 |
| 31 Dec 21 | 4 | -53 | 26 | 15 |
| 30 Sep 21 | 5 | -50 | 23 | 12 |
| 30 Jun 21 | 7 | -46 | 23 | 10 |
| 31 Mar 21 | 10 | -42 | 21 | 7 |
| 31 Dec 20 | 9 | -39 | 20 | 6 |
| 30 Sep 20 | 8 | -35 | 21 | 6 |
| 30 Jun 20 | 7 | -39 | 20 | 6 |
| 31 Mar 20 | 5 | -45 | 20 | 6 |
| 31 Dec 19 | 6 | -45 | 20 | 6 |
| 30 Sep 19 | 6 | -48 | 21 | 4 |
| 30 Jun 19 | 6 | -43 | 22 | 3 |
| 31 Mar 19 | 5 | -34 | 22 | 1 |
| 31 Dec 18 | 4 | -32 | 22 | 0 |
| 30 Sep 18 | 4 | -41 | 21 | 0 |
| 30 Jun 18 | 4 | -30 | 16 | 0 |
| 31 Mar 18 | 4 | -24 | 13 | 0 |
| 31 Dec 17 | 4 | -22 | 11 | 0 |
| 30 Sep 17 | 3 | -5 | 8 | 0 |
| 30 Jun 17 | 2 | -14 | 9 | 0 |
| 31 Mar 17 | 1 | -17 | 9 | 0 |
| 31 Dec 16 | 0 | -15 | 6 | 0 |
| 31 Dec 15 | 0 | 5 | 3 | 2 |
Quality Earnings: 1JA is currently unprofitable.
Growing Profit Margin: 1JA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1JA is unprofitable, and losses have increased over the past 5 years at a rate of 1.7% per year.
Accelerating Growth: Unable to compare 1JA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1JA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).
Return on Equity
High ROE: 1JA has a negative Return on Equity (-271.78%), as it is currently unprofitable.